Amgen Drug Succeeds in Late-Stage Sjögren’s Disease Trial
Amgen’s dazodalibep met its Phase 3 goal in moderate-to-severe Sjögren’s disease, showing lasting improvement in systemic activity. A second trial is due later in 2026.
/ 12 items
#AMGN↓
Amgen Slides After BMO Downgrade and Rival Heart-Drug Miss
BMO cut Amgen to Market Perform on valuation after a 34% YTD rally. A Novartis Lp(a) trial miss also raises questions for Amgen’s olpasiran.
Amgen’s Easy “On-Body” Tepezza Shot Crushes Phase 3 — Viridian Stock Plunges
Viridian shares fell after Amgen’s new, easy Tepezza shot showed strong results for Thyroid Eye Disease.
Upstream Bio's Asthma Drug Hits Goal but Misses Top Hopes
Upstream Bio's Phase 2 trial for verekitug shows strong results in cutting asthma attacks, but only the every-12-week dose matches rivals. Stock dips as experts weigh in on future plans and competition.
Amgen Beats Q4 Expectations Despite FDA Drug Controversy
Amgen (AMGN) reports strong Q4 2025 earnings with $9.87B revenue, beating estimates. Company defies FDA request to withdraw Tavneos while advancing obesity drug MariTide through trials.
Zenas BioPharma Crashes 53% Despite Meeting Trial Goals—Why Investors Aren't Buying It
Zenas BioPharma stock plunges over 50% after Phase 3 obexelimab trial results disappoint Wall Street, despite meeting all endpoints in rare autoimmune disease study.